This study investigates the role of M2-exo-mediated HOXC13-AS in laryngeal squamous cell carcinoma (LSCC) by examining its transmission to tumor microenvironment (TME) macrophages. Exosomes from M2 macrophages were isolated and characterized using transmission electron microscopy, nanoparticle tracer analysis and western blot. Expression of HOXC13-AS, miR-485-5p, IGF2BP2, and PD-L1 was analyzed. Different interventions on LSCC cell function and immune escape were detected using molecular biological techniques. The study found that elevated HOXC13-AS were present in LSCC, and M2-exo expression was significantly increased in LSCC cells. Silencing HOXC13-AS in M2-exo inhibited LSCC malignant progression and immune escape in vivo and in vitro. M2-exo-mediated HOXC13-AS also regulated IGF2BP2 expression, impacting cellular biological function and immune escape process. The study concludes that M2-exo-mediated HOXC13-AS promotes LSCC malignancy and immune escape.
基金：
Capital Health Research and Development of Special [2022-1-2051]
第一作者机构：[1]Capital Med Univ, Beijing Tongren Hosp, Dept Otorhinolaryngol Head & Neck Surg, Beijing, Peoples R China[2]Capital Med Univ, Minist Educ, Key Lab Otorhinolaryngol Head & Neck Surg, Beijing, Peoples R China
通讯作者：
通讯机构：[1]Capital Med Univ, Beijing Tongren Hosp, Dept Otorhinolaryngol Head & Neck Surg, Beijing, Peoples R China[2]Capital Med Univ, Minist Educ, Key Lab Otorhinolaryngol Head & Neck Surg, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
He Shizhi,He Yurong,Zhu Siyu,et al.M2 Macrophage exosomal HOXC13-AS in laryngeal cancer immunity via targeting miR-485-5p/IGF2BP2/PD-L1[J].INTERNATIONAL IMMUNOPHARMACOLOGY.2024,140:doi:10.1016/j.intimp.2024.112742.
APA：
He, Shizhi,He, Yurong,Zhu, Siyu,Wang, Ru,Liu, Shaokun...&Fang, Jugao.(2024).M2 Macrophage exosomal HOXC13-AS in laryngeal cancer immunity via targeting miR-485-5p/IGF2BP2/PD-L1.INTERNATIONAL IMMUNOPHARMACOLOGY,140,
MLA：
He, Shizhi,et al."M2 Macrophage exosomal HOXC13-AS in laryngeal cancer immunity via targeting miR-485-5p/IGF2BP2/PD-L1".INTERNATIONAL IMMUNOPHARMACOLOGY 140.(2024)
医学